



The president of Medicines for Europe talks about what the European healthcare sector needs and what the off-patent sector can deliver.
Read the comment of our President and full Article below.
At Medicines for Europe’s Legal and Annual Conferences in Brussels last week, multiple key issues were discussed to support the role of generics and biosimilars at a critical time for EU pharma reform.
Read the comment of our President and full Article below.